Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity
Author(s) -
Bertrand Lecointre,
Remy Narozny,
María Teresa Borrello,
Johanna Senger,
Alokta Chakrabarti,
Manfred Jung,
Martin Marek,
Christophe Romier,
Jelena Melesina,
Wolfgang Sippl,
Laurent Bischoff,
A. Ganesan
Publication year - 2018
Publication title -
philosophical transactions of the royal society b biological sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.753
H-Index - 272
eISSN - 1471-2970
pISSN - 0962-8436
DOI - 10.1098/rstb.2017.0364
Subject(s) - gene isoform , functional diversity , diversity (politics) , chemistry , hdac1 , biochemistry , computational biology , stereochemistry , biology , gene , political science , ecology , histone , law , histone deacetylase
A series of hydroxamic acids linked by different lengths to a chiral imidazo-ketopiperazine scaffold were synthesized. The compounds with linker lengths of 6 and 7 carbon atoms were the most potent in histone deacetylase (HDAC) inhibition, and were specific submicromolar inhibitors of the HDAC1, HDAC6 and HDAC8 isoforms. A docking model for the binding mode predicts binding of the hydroxamic acid to the active site zinc cation and additional interactions between the imidazo-ketopiperazine and the enzyme rim. The compounds were micromolar inhibitors of the MV4-11, THP-1 and U937 cancer cell lines. Increased levels of histone H3 and tubulin acetylation support a cellular mechanism of action through HDAC inhibition. This article is part of a discussion meeting issue ‘Frontiers in epigenetic chemical biology’.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom